Wang X, Liang J H
Ophthalmology Department, Cangzhou Central Hospital, Hebei Province, Cangzhou 061001, China.
Beijing Key Laboratory of Vision Loss and Restoration, Ministry of Education, Department of Ophthalmology, People's Hospital, Peking University, Beijing 100044, China.
Zhonghua Yan Ke Za Zhi. 2019 Apr 11;55(4):294-301. doi: 10.3760/cma.j.issn.0412-4081.2019.04.012.
To investigate the treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor. Retrospective study of 5 patients(8 eyes) diagnosed retinopathy of incontinentia pigmenti from 2005 to 2017, including 0 males and 5 females (8 eyes involved) with an average age of 2.4 months(range, 1-5 months). Medical history and family history were recorded in detail for all children. We did the examination of anterior segment of the eyeball, vitreous body,fundus and intraocular pressure for the 5 patients(8eyes).What's more,wo also took pictures for fundus with the machine of Retcam. Fundus fluorescence angiography (FFA) was performed in 2 patients(4 eyes). Different surgical methods were selected according to the specific conditions of the eye and postoperative were observed. At the time of initial diagnosis, preretinal hemorrhage did not affect the macular region in 3 cases (5 eyes), pre retinal hemorrhage affected the macular region in 1 case(1 eye), the retinal neovascularization in 3 cases(5 eyes), the retinal detachment in 2 cases(2 eyes), and nonvascular zone of peripheral retinal in 5cases(8 eyes). Treatment and drug selection: 3 cases(5 eyes) were treated with injection anti-VEGF drug into vitreous body cavity, 1 case(1 eye) was treated with injection anti-VEGF drug into vitreous body cavity plus laser photocoagulation, 1 case(1 eye) was treated with anti-VEGF drugs plus vitrectomy. 1 case(1 eye) was treated with anti-VEGF drugs plus retinal cryotherapy and sclera bucking. In patients of injection anti-VEGF drug into vitreous body cavity, 2 cases(3 eyes) were given a single dose and 1 case (2 eyes) was given a repeated dose. Drug selection: 4 cases(6 eyes) ranibizumab injection (injection dose 0.025 ml), 1 case (2 eyes)conbercept injection (injection dose 0.025 ml). To follow-up date, etina was flat in 4 patients (7 eyes), epiretinal membrane in 2 patients(2 eyes), retinal detachment in 1 patient(1 eye). The efficacy of anti-vascular endothelial growth factor in the treatment of retinopathy of incontinentia pigmenti was prelininarily confimed.However,the optimal use timing,dosage,local and systemic safety issues were needed to be further studied. .
探讨抗血管内皮生长因子治疗色素失禁症视网膜病变的效果。回顾性研究2005年至2017年确诊为色素失禁症视网膜病变的5例患者（8只眼），其中男性0例，女性5例（累及8只眼），平均年龄2.4个月（范围1 - 5个月）。详细记录所有患儿的病史和家族史。对这5例患者（8只眼）进行了眼球前段、玻璃体、眼底及眼压检查。此外，还用Retcam眼底成像仪进行了眼底拍照。2例患者（4只眼）进行了眼底荧光血管造影（FFA）。根据眼部具体情况选择不同手术方法并观察术后情况。初诊时，3例（5只眼）视网膜前出血未累及黄斑区，1例（1只眼）视网膜前出血累及黄斑区，3例（5只眼）有视网膜新生血管，2例（2只眼）有视网膜脱离，5例（8只眼）有周边视网膜无血管区。治疗及药物选择：3例（5只眼）采用玻璃体腔注射抗VEGF药物治疗，1例（1只眼）采用玻璃体腔注射抗VEGF药物联合激光光凝治疗，1例（1只眼）采用抗VEGF药物联合玻璃体切除术治疗，1例（1只眼）采用抗VEGF药物联合视网膜冷冻疗法及巩膜外加压术治疗。在玻璃体腔注射抗VEGF药物的患者中，2例（3只眼）给予单次剂量，1例（2只眼）给予重复剂量。药物选择：4例（6只眼）使用雷珠单抗注射液（注射剂量0.025 ml），1例（2只眼）使用康柏西普注射液（注射剂量0.025 ml）。至随访时，4例患者（7只眼）视网膜平复，2例患者（2只眼）有视网膜前膜，1例患者（1只眼）有视网膜脱离。初步证实抗血管内皮生长因子治疗色素失禁症视网膜病变有效。然而，最佳使用时机、剂量、局部及全身安全性问题仍需进一步研究。
